Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis

无容量 医学 中止 肺癌 免疫疗法 肿瘤科 化疗 内科学 癌症
作者
Matteo Giaj Levra,François-Emery Cotté,Romain Corre,C. Calvet,Anne-Françoise Gaudin,John R. Penrod,V. Grumberg,B. Jouaneton,R. Jolivel,Jean‐Baptiste Assié,C. Chouaïd
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:140: 99-106 被引量:94
标识
DOI:10.1016/j.lungcan.2019.12.017
摘要

Abstract

Objectives

Nivolumab is now a reference treatment for patients with advanced non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy. Little data are available on treatment approaches following discontinuation of nivolumab and on the interest of a second course of immunotherapy after nivolumab discontinuation. The aims of this study were to describe treatment pathways following nivolumab discontinuation and to describe survival following retreatment with immunotherapy.

Materials and methods

The analysis includes all patients with NSCLC recorded in a national hospital database, starting nivolumab in 2015-2016. Nivolumab treatment was considered discontinued if ≥3 infusions were missed. Patients starting a second course of PD-1 inhibitor following nivolumab discontinuation were analysed according to the duration of their initial nivolumab treatment course.

Results

10,452 patients were included (71 % men; mean age: 63.8 ± 9.6 years; squamous histology: 44 %). Median nivolumab treatment duration was 2.8 months [IQR :1.4–6.9]. Median OS was 11.5 months [95 %CI: 11.1–11.9]; 5118 (53.4 %) patients received post nivolumab therapy lines: 1517 (29.6 %) of these received a second course of PD-1 inhibitor, either after a treatment-free interval (resumption: n=1127) or after intervening chemotherapy (rechallenge: n=390). Median OS after nivolumab discontinuation was 15.0 months [13.9–16.7] in the resumption group and 18.4 months [14.8–21.9] in the rechallenge group. Median OS was significantly longer in patients with an initial nivolumab treatment duration ≥3 months.

Conclusion

In this real-world setting, outcome after retreatment with a PD-1 inhibitor following a first course of nivolumab was significantly better in patients with a longer duration of initial nivolumab treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
窗外落霞发布了新的文献求助10
刚刚
JamesPei应助苏苏采纳,获得10
1秒前
1秒前
喻箴发布了新的文献求助10
2秒前
微笑的桐发布了新的文献求助10
2秒前
不良帅完成签到,获得积分10
3秒前
IvanMcRae应助蓝色的云采纳,获得10
4秒前
老朱发布了新的文献求助10
4秒前
4秒前
zxf发布了新的文献求助10
4秒前
迷人问兰完成签到,获得积分10
7秒前
李富贵完成签到,获得积分20
8秒前
哭泣的俊驰完成签到,获得积分20
8秒前
8秒前
9秒前
xyg发布了新的文献求助10
11秒前
量子星尘发布了新的文献求助10
11秒前
12秒前
YouzhiYe关注了科研通微信公众号
13秒前
仁爱的尔蓝完成签到 ,获得积分10
13秒前
zXX发布了新的文献求助10
14秒前
苏苏发布了新的文献求助10
14秒前
15秒前
小木木壮发布了新的文献求助50
16秒前
害怕的友蕊完成签到,获得积分20
16秒前
老迟到的土豆完成签到 ,获得积分10
17秒前
17秒前
ALICE发布了新的文献求助10
18秒前
烟花应助郭志晟采纳,获得10
18秒前
19秒前
Luke完成签到,获得积分10
19秒前
曾经二娘发布了新的文献求助10
19秒前
研友_Z3vN0n发布了新的文献求助10
19秒前
summer完成签到,获得积分10
19秒前
水流众生完成签到 ,获得积分10
19秒前
圣殿幻龙完成签到,获得积分10
20秒前
米粒发布了新的文献求助10
21秒前
Stroeve完成签到,获得积分10
21秒前
调皮德地完成签到,获得积分20
22秒前
水果完成签到,获得积分10
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970048
求助须知:如何正确求助?哪些是违规求助? 3514739
关于积分的说明 11175783
捐赠科研通 3250115
什么是DOI,文献DOI怎么找? 1795198
邀请新用户注册赠送积分活动 875630
科研通“疑难数据库(出版商)”最低求助积分说明 804951